Catalyst and Angelini Pharma Merger Receives Early Termination of Waiting Period Under HSR Act

MT Newswires Live06-24

Catalyst Pharmaceuticals' (CPRX) merger agreement with Angelini Pharma and Angelini Cielo received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act from the US Federal Trade Commission, Catalyst said in a late Tuesday filing.

The merger agreement reached in May would result in Catalyst becoming a wholly owned subsidiary of Angelini Pharma.

Catalyst said it and Angelini Pharma each filed a Premerger Notification and Report Form under the HSR Act on May 20, and the FTC granted early termination of the waiting period on June 16.

The transaction remains subject to other customary closing conditions, and the parties expect the merger to close in the third quarter, Catalyst said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment